Nisa Investment Advisors LLC Acquires 8,261 Shares of Insmed, Inc. $INSM

Nisa Investment Advisors LLC grew its holdings in Insmed, Inc. (NASDAQ:INSM) by 374.6% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,466 shares of the biopharmaceutical company’s stock after acquiring an additional 8,261 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Insmed were worth $1,507,000 at the end of the most recent reporting period.

A number of other hedge funds also recently modified their holdings of the business. Financiere des Professionnels Fonds d investissement inc. acquired a new position in shares of Insmed in the 2nd quarter valued at approximately $452,000. Longboard Asset Management LP acquired a new position in shares of Insmed in the second quarter valued at approximately $205,000. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Insmed by 17.9% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 4,446 shares of the biopharmaceutical company’s stock worth $435,000 after acquiring an additional 674 shares during the period. Fulton Bank N.A. lifted its position in Insmed by 21.0% in the 2nd quarter. Fulton Bank N.A. now owns 5,416 shares of the biopharmaceutical company’s stock valued at $545,000 after acquiring an additional 940 shares in the last quarter. Finally, Assenagon Asset Management S.A. boosted its stake in Insmed by 84.5% in the 2nd quarter. Assenagon Asset Management S.A. now owns 73,404 shares of the biopharmaceutical company’s stock worth $7,387,000 after purchasing an additional 33,626 shares during the period.

Insider Activity at Insmed

In other Insmed news, Director Elizabeth M. Anderson sold 10,000 shares of the business’s stock in a transaction that occurred on Friday, November 14th. The stock was sold at an average price of $195.87, for a total transaction of $1,958,700.00. Following the transaction, the director owned 63,729 shares of the company’s stock, valued at $12,482,599.23. The trade was a 13.56% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Michael Alexander Smith sold 27,130 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $183.78, for a total value of $4,985,951.40. Following the completion of the sale, the insider directly owned 54,902 shares of the company’s stock, valued at approximately $10,089,889.56. The trade was a 33.07% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 286,100 shares of company stock worth $52,595,894 over the last ninety days. Company insiders own 3.00% of the company’s stock.

Insmed Trading Down 0.2%

Shares of Insmed stock opened at $163.46 on Thursday. The stock has a market cap of $34.86 billion, a P/E ratio of -26.41 and a beta of 1.08. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. Insmed, Inc. has a 12-month low of $60.40 and a 12-month high of $212.75. The business’s 50 day moving average is $188.82 and its 200-day moving average is $153.50.

Insmed (NASDAQ:INSM) last released its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The firm had revenue of $142.34 million during the quarter, compared to the consensus estimate of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. Insmed’s quarterly revenue was up 52.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.27) earnings per share. Equities research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the company. Cantor Fitzgerald lifted their price target on Insmed from $216.00 to $230.00 and gave the company an “overweight” rating in a research note on Tuesday, December 16th. Guggenheim dropped their target price on Insmed from $230.00 to $221.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Jefferies Financial Group set a $269.00 target price on Insmed in a research note on Wednesday, December 10th. Wolfe Research set a $167.00 price target on shares of Insmed and gave the stock an “outperform” rating in a research note on Thursday, December 18th. Finally, Redburn Partners set a $263.00 price objective on shares of Insmed in a report on Thursday, December 4th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Insmed presently has a consensus rating of “Moderate Buy” and an average target price of $205.77.

Insmed Company Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.